Header cover image
  • Investing Ideas
  • /
  • Taiwanese Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20

Taiwanese Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20

Results

4

0 new

A list of companies that grew earnings by 20% and are trading on less than 20 times earnings. All with a debt to equity ratio below 1.

4 companies

Lotus Pharmaceutical

Market Cap: NT$70.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.

1795

NT$266.00

7D

4.3%

1Y

3.1%

TTY Biopharm

Market Cap: NT$19.6b

Engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally.

4105

NT$78.70

7D

1.3%

1Y

7.2%

Maxigen Biotech

Market Cap: NT$3.8b

Researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally.

1783

NT$47.05

7D

5.3%

1Y

12.2%

TSH Biopharm

Market Cap: NT$2.0b

Develops and markets pharmaceutical products in Taiwan and Asia.

8432

NT$52.00

7D

-1.1%

1Y

-12.6%